Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.

There was also a longer TTD in symptoms of the composite end point of cough, chest pain, or dyspnea in the pembrolizumab plus EP group versus placebo plus EP group, although the between-group treatment differences did not reach statistical significance.

also in 111,027 other papers